Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019).
| Primary exchange (MIC) | XNAS |
|---|---|
| Listed since | 1983-06-17 |
| Market capitalization | $223.2 billion |
| Shares outstanding | 540,632,005 |
| Employees | 31,500 |
| Headquarters | THOUSAND OAKS, CA, US |
| Website | www.amgen.com |
AMGN has traded between $415.20 and $428.05 in the current session, a range of $12.85. The latest price of $429.89 sits near the top of that range (114% of the way from low to high). The volume-weighted average price is $425.53, and the stock is trading above it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.
| High | $428.05 |
|---|---|
| Low | $415.20 |
| Previous close | $412.84 |
| Volume | 3,085,210 |
| VWAP | $425.53 |
StockMarketLoop's Market Position model estimates how the shares traded between 2026-07-17 and 2026-10-15 were bought. Its estimate of the average cost basis is $405.96; at $429.89 the stock trades 5.9% above that level. About 86.4% of those shares are estimated to be held at a profit at the current price. A high figure means most recent buyers are in the green, which can mean fewer trapped holders overhead, and also more people with gains who might sell. The densest nearby clusters of cost basis sit around $415.56 (support) and $437.52 (resistance). Roughly 70% of the estimated cost basis lies between $381.17 and $425.08, and 90% between $375.31 and $439.71.
This is a model estimate built from price and volume history, not a record of actual positions.
Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.